Skip to Late-Breaking Abstracts »
All accepted abstracts are available in the Journal for ImmunoTherapy of Cancer (JITC).
Abstract Titles
Poster Presentation Dates
All odd numbered posters will be presented on Wednesday, Nov. 11, from 5:15-5:45 p.m. EST and Friday, Nov. 13, from 4:40-5:10 p.m. EST. Even numbered posters will be presented on Thursday, Nov. 12, from 4:50-5:20 p.m. EST and Saturday, Nov. 14, from 1-1:30 p.m. EST.
Posters will be on display from 8 a.m. on Monday, Nov. 9, until the virtual poster hall closes on December 31, 2020.
| # | Type | Title | Authors | Category | Keywords |
|---|---|---|---|---|---|
| 17 | Poster Presentation | Activity sensors for noninvasive monitoring of immune response and tumor resistance during immune checkpoint blockade therapy | Quoc Mac, BS; James Bowen; Hathaichanok Phuengkham; Anirudh Sivakumar; Congmin Xu; Fang-Yi Su; Samuel Z. Stentz; Hyoung Sim; Adrian Harris; Tonia Li; Peng Qiu; Gabriel Kwong; Quoc Mac, BS; | Biomarkers, Immune Monitoring and Novel Technologies | Antibody; Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Immune monitoring; T cell; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 179 | Poster Presentation | Immunotherapy trials lack a biomarker for inclusion: implications for drug development | Jacob J. Adashek, DO; Alexey Goloubev; Shumei Kato, MD; Razelle Kurzrock, MD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Clinical study |
| 180 | Poster Presentation | The effect of packed red blood cell transfusions on the clinical efficacy of immunotherapy | Christopher D'Avella, MD; Karthik Devarajan, PhD; Martin Edelman, MD; Daniel M. Geynisman, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune suppression; Solid tumors |
| 181 | Poster Presentation | Anlyasis of Therapeutic effect and safty of PD-1 Inhibitors in Clinical treatment of Oral and Maxillofacial malignant tumors | Haochuan Liu; Yaqiong Jie; Xinguang Han; | Checkpoint Blockade Therapy | Angiogenesis; Antibody; Antigen presenting cells; Checkpoint blockade; Clinical study; Clinical trial; Immune contexture; Immune suppression; Surgery; T cell |
| 182 | Poster Presentation | Highly Potent Fully Human Anti-VISTA Antibodies – A New Target Checkpoint Inhibitor against Immunosuppressive Myeloid Cells. | Thierry Guillaudeux; Eric Tarcha; Robert Bader; Benjamin Dutzar; Nathan Eyde; Emily Frazier; David Jurchen; Remington Lance; Cristina Loomis; Kurt Lustig; Yulia Ovechkina; David Peckham; Shaarwari Sridhar; Mei Xu; Shawn Iadonato; Jeff Posakony; | Checkpoint Blockade Therapy | Antibody; Antigen presenting cells; Checkpoint blockade; Immune suppression; MDSC; Monocyte/Macrophage; Myeloid cells; Regulatory T cell (Treg cell); Targeted therapy; Tumor microenvironment |
| 183 | Poster Presentation | Overcoming immunotherapy resistance in T cell-inflamed lung cancer | Brendan L. Horton, PhD; Duncan Morgan; Noor Momin; Vidit Bhandarkar; Dane Wittrup, PhD; Chris Love, PhD; Stefani Spranger, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Cytokine; Immune contexture; Immune suppression; Immune tolerance; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| 184 | Poster Presentation | Two types of anti-TIGIT antibodies with distinct binding epitope and functional activities | Tingting Zhong, MS; Xinghua Pang, BSc; Zhaoliang Huang, BSc; na chen, MD; Xiaoping Jin, PhD; Yu Xia, PhD; Maxwell Zhongmin Wang, PhD; Baiyong Li, PhD; Yu Xia, PhD; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade |
| 185 | Poster Presentation | Camrelizumab monotherapy or combination therapy in patients with recurrent or metastatic cervical and endometrial carcinoma：a retrospective study | Hong Liu, MD; Hong Liu, MD; Shuhuai Niu; Zhaohui Fang; Xi Chen; Qianying Zhang; | Checkpoint Blockade Therapy | Antibody; Biomarkers; Checkpoint blockade; Chemotherapy; Clinical study; Cytokine; Immune toxicity; Radiotherapy; Solid tumors; T cell |
| 186 | Poster Presentation | Distinct immune signatures predicting clinical response to PD-1 blockade therapy in gynecological cancers revealed by high-dimensional immune profiling. | Yuki Muroyama, MD, PhD; Sasikanth Manne; Alexandar C. Huang, MD; Divij Mathew, PhD; Lakshmi Chilukuri; Allison R. Greenplate, PhD; Takuya Ohtani, PhD; Dmitriy Zamarin, MD, PhD; Claire F. Friedman, MD; John Wherry, PhD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 187 | Poster Presentation | Real-world treatment patterns and clinical predictors of overall survival among anti-PD-1 exposed advanced melanoma patients with documented evidence of disease progression. | Cathy Anne Pinto, Ph.D.; Xinyue Liu; Xiaoyun Li; Emilie Scherrer; Mizuho Kalabis; Cathy Anne Pinto, Ph.D.; | Checkpoint Blockade Therapy | Checkpoint blockade; Epidemiology |
| 188 | Poster Presentation | Novel Anti-SIRPalpha Antibodies with Differentiated Characteristics as Promising Cancer Therapeutics | Minu K. Srivastava, PhD; Swati Jalgaonkar; George Huang; Erin L. Filbert, PhD; Christine Tan; Ryan Alvarado; Sushma Krishnan, MSc in Biology; Rena Bahjat; Xiaodong Yang, MD, PhD; | Checkpoint Blockade Therapy | Antibody; Antigen presenting cells; Checkpoint blockade; Dendritic cell; Immune suppression; MDSC; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor microenvironment |
| 189 | Poster Presentation | A clear increase in TILs and modest tumor growth inhibition by pembrolizumab in prostate cancer tumors growing in bone of CD34+ engrafted NOG mice | Suominen I. Suominen, PhD; Justyna Zdrojewska, PhD; Jenni Mäki-Jouppila, PhD; Philip Dube, PhD; Ivan Gladwyn-Ng, PhD; Paul Volden, PhD; Jukka Rissanen, PhD; Mari I. Suominen, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 190 | Poster Presentation | Timing of steroid doses and response rates to immune-checkpoint inhibitors in metastatic cancer | Karine Tawagi, MD; Diana V. Maslov, MD, MS; Victoria Simenson, MD; Helen Yuan; Cameron Parent; Adi Bamnolker; Richa Goel; Zoe Blake; Madhav KC; Marc Matrana; Karine Tawagi, MD; Daniel Johnson, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune toxicity; Solid tumors |
| 191 | Poster Presentation | Association of immune related adverse events with the efficacy of immune checkpoint inhibitors in metastatic renal cell carcinoma | Vasilii Bushunow, MD; Leonard J. Appleman, MD, PhD; Roby Thomas, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune toxicity; Solid tumors |
| 192 | Poster Presentation | 'Immune-Brain': A case series of cognitive dysfunction/decline in cancer patients on immunotherapy | Sarah R. Gillett, MD, PhD; Ximena Jordan-Bruno, MD; Hibba Rehman, MD; Alissa Thomas, MD; Sarah R. Gillett, MD, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune toxicity; Solid tumors |
| 193 | Poster Presentation | Differences In Thyroid Immune-Related Adverse Events Between Lung Cancer Types, A Retrospective Analysis | Rahim A. Jiwani, MD; Heather Brody; Yuxuan Mao, MD, MS; Elisabeth Lee, PhD; Rita Rehana, MD; Cynthia Cherry; Hui Bian, PhD; Praveen Namireddy, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune toxicity |
| 194 | Poster Presentation | A multicenter characterization of chronic toxicities following adjuvant anti-PD-1 therapy for high risk resected melanoma | James R. Patrinely, Jr., BA; Rebecca Johnson, B.HlthSc, M.N; Aleigha R. Lawless, B.S.; Prachi Bhave, M.D.; Amelia Sawyers, B.S.; Maya Dimitrova, M.D.; Hui L. Yeoh, M.B.B.S., B.Med.Sc.; Marisa Palmeri, B.S.; Elizabeth J. Davis, M.D.; Suthee Rapisuwon, M.D.; Georgina V. Long, M.D., Ph.D.; Andrew Haydon, M.D., Ph.D.; Iman Osman, M.D.; Janice M. Mehnert, M.D.; Matteo S. Carlino, M.D., Ph.D.; Ryan J. Sullivan, M.D.; Alexander M. Menzies, M.D., Ph.D.; Douglas B. Johnson, M.D.; | Checkpoint Blockade Therapy | Checkpoint blockade; Clinical study; Immune adjuvant; Immune toxicity; Targeted therapy |
| 195 | Poster Presentation | Avelumab internalization and lysosomal degradation by circulating immune cells in human is mediated by both Fc gamma Receptor (FcgR) and PD-L1 binding | Hulin Jin, Ph.D; Vittorio D'Urso; Berend Neuteboom; Sean D. McKenna; Rene Schweickhardt; Alec W. Gross; Yves Fomekong Nanfack; Lars Toleikis; Markus Fluck; Juergen Scheuenpflug, PhD; Ti Cai; | Checkpoint Blockade Therapy | Antibody; Biomarkers; Checkpoint blockade |
| 196 | Poster Presentation | Checkpoint blockade therapy for brain-metastatic non-small cell lung cancer: a comparative effectiveness analysis of national data | Nayan Lamba, MD; Bryan Iorgulescu, MD; | Checkpoint Blockade Therapy | Checkpoint blockade |
| 197 | Poster Presentation | Survival outcomes and toxicity among patients treated with concomitant radiotherapy and immunotherapy for advanced melanoma: two faces of the abscopal effect? | Nikolaos Andreatos, MD; Joanna Roopkumar, MBBS, MPH; Alok A. Khorana, MD; Neil M. Woody, MD, MS; Brian R. Gastman, MD; Pauline Funchain, MD; | Checkpoint Blockade Therapy | Autoimmunity; Checkpoint blockade; Immune toxicity; Radiotherapy; Solid tumors; Tumor antigens |
| 198 | Poster Presentation | Combination intratumoral treatment with INTASYL™ self-delivering RNAi targeting TIGIT and PD-1/PD-L1 improves tumor control compared to monotherapy in a CT26 model of murine colorectal cancer | Benjamin Cuiffo, PhD; Melissa Maxwell, MS; Dingxue Yan; Andrej Jedinak, PhD; James Cardia, PhD; Simon P. Fricker, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Coinhibition; Gene expression; RNA; T cell; Targeted therapy; Tumor microenvironment |
| 199 | Poster Presentation | Enhanced immune responses in human breast and colon cancer following checkpoint therapy in a CD34+ stem cell humanized NCG (HuCD34NCG) mouse model | Christoph S. Eberle, PhD; Jenny Rowe, PhD; Ann Fiore, BS; Robert Mihalek, PhD; Stephen Festin, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 200 | Oral Presentation | NBTXR3 nanoparticle with immunoradiation improves survival and generates long-term anti-tumor memory in an anti-PD1 resistant Murine Lung Cancer Model | Yun Hu, PhD; James W. Welsh, MD; Sebastien Paris, PhD; Hampartsoum Barsoumian, PhD; Chike O. Abana; Saumil Gandhi; Quynh N. Nguyen; Maria A. Cortez, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 201 | Poster Presentation | Carboplatin, paclitaxel and pembrolizumab for the first line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma | Angelica Valadez; Madeleine Welsh; Christine Kim; Angela Johns; Alain P. Algazi, MD; Hyunseok Kang, MD, MPH; Hyunseok Kang, MD, MPH; | Checkpoint Blockade Therapy | Checkpoint blockade; Chemotherapy; Clinical study; Solid tumors |
| 202 | Poster Presentation | In vitro and in vivo combination therapy of Low Molecular Weight Heparins, chemotherapy and immunotherapy, induce antitumor activity in Pancreatic Cancer | Michalis Karamouzis; Panagiotis Sarantis, MD, PhD; Evangelos Koustas; Adriana Papadimitropoulou; Pavlos Papakotoulas; Alexandros Bokas; Dimitrios Schizas; Alexandros Papalampros; Evangelos Felekouras; Theodoros Liakakos; Athanasios Papavassiliou; | Checkpoint Blockade Therapy | Checkpoint blockade; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 203 | Poster Presentation | Preclinical characterization and development of MG1124, a Novel Immune Checkpoint inhibitor targeting CEACAM1 for NSCLC patients | Jae-Chul Lee, MS; Woo Seok Yang; Hye-Young Park; Hye-mi Nam; Hyun-Jung Cho; Mi-Young Oh; Eun-Young Kwak; Jinhyun Park; Myeng Eun Jung; Hawook Chung; Minju Kim; Jae-Hwan Kim, PhD; Byoung Chul c. Cho, MD, PhD; | Checkpoint Blockade Therapy | Antibody; Biomarkers; Checkpoint blockade; Immune suppression; NK/NK T cell; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 204 | Poster Presentation | The role of immune checkpoint inhibitor as a single agent or combination therapy in advanced thyroid cancer | Ju Young Lee; Ju Young Lee, MD; Inae Park; Myungwoo Nam, MD; Christmann Low; Eugene Kim; Hansol Choi; Elena Vagia; Chan Mi Jung; Young Kwang Chae, MD, MPH, MBA; | Checkpoint Blockade Therapy | Checkpoint blockade; Clinical study; Clinical trial |
| 205 | Poster Presentation | PD-1/PD-L1/CTLA-4 inhibitor therapy following progression on a different PD-1/PD-L1 inhibitor: a case series | Suresh Mukkamala, MD; Suresh Mukkamala, MD; Suresh Mukkamala, MD; Karine Tawagi, MD; Marc R. Matrana, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Clinical study; Immune toxicity; Tumor microenvironment |
| 206 | Oral Presentation | An immune-competent tumor organoid platform to test novel immune checkpoint combinations targeting the receptor CD47 in triple negative breast cancer | Elizabeth R. Stirling, MS; Ethan Willey-Shelkey; Adam Wilson; Aleksander Skardal, PhD; Pierre L. Triozzi, MD; Masaki Terabe, PhD; Lance D. Miller, MS, PhD; Shay Soker, PhD; David R. Soto-Pantoja, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Metabolism; Solid tumors; T cell; Tumor microenvironment |
| 207 | Poster Presentation | Small molecule inhibitors of Sec61 cotranslational translocation regulate the phagocytosis checkpoint molecule CD47 | Jennifer A. Whang, PhD; Jennifer A. Whang, PhD; Andrea Fan, PhD; Christopher J. Kirk, PhD; Eric Lowe, BS; Dustin McMinn, PhD; Beatriz Millare, BS; Meera Rao, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Monocyte/Macrophage; Tumor evasion; Tumor microenvironment |
| 208 | Poster Presentation | E7777 (denileukin diftitox) enhances anti-tumor activity and significantly extends survival benefit of anti-PD-1 in syngeneic solid tumor models | Mary Woodall-Jappe, Ph.D.; A. Raghav Chari; Anil N. Namboodiripad; Chandrasekhar Goda; | Checkpoint Blockade Therapy | Regulatory T cell (Treg cell); Solid tumors; T cell |
| 209 | Oral Presentation | Preclinical mechanistic and clinical evaluation of the corticosteroid dexamethasone’s detrimental effects on immune checkpoint blockade in glioblastoma cancer | Bryan Iorgulescu, MD; Prafulla C. Gokhale, PhD; Maria Speranza, PhD; Benjamin Eschle; Michael Poitras; Margaret Wilkens; Kara Soroko; Chhayheng Chhoeu; Aine Knott; Yan Gao; Mary Jane Lim-Fat; Gregory Baker; Dennis Bonal; Quang-Dé Nguyen; Gareth Grant; Keith Ligon; Peter K. Sorger; E Chiocca, MD; Ana C. Anderson, PhD; Paul T. Kirschmeier, PhD; Arlene H. Sharpe, MD, PhD; Gordon J. Freeman, PhD; David A. Reardon, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Clinical study; Immune suppression; Tumor infiltrating lymphocytes (TILs) |
| 210 | Poster Presentation | Regulation of TIM-3 by phosphatidylserine | Courtney M. Smith, BS; Alice Li; Nithya Krishnamurthy; Mark A. Lemmon, PhD, FRS; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Coinhibition; T cell |
| 211 | Poster Presentation | Targeting BTN2A1 modulates anti-tumor activity of Vg9Vd2 T Cells | Carla E. Cano, Ph.D.; Aude de Gassart, PhD; Christine Pasero, PhD; Melanie Gabriac; Marie Fullana; Emilie Granarolo; Rene Hoet; Caroline Imbert; Laurent Gorvel; Antoine Briantais; Anne-Charlotte Le Floch; Daniel Olive, Md, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; T cell; T cell lineages; Targeted therapy; Tumor microenvironment |
| 212 | Poster Presentation | CLEC-1 is a novel myeloid immune checkpoint for cancer immunotherapy limiting tumor cells phagocytosis and synergizing with tumor-targeted antibodies. | Vanessa Gauttier; Marion Drouin; Sabrina Pengam; Javier Saenz; Bérangère Evrard; Caroline Mary; Géraldine Teppaz; Ariane Desselle; Virginie Thépénier; Emmanuelle Wilhelm; Elise Chiffoleau; Nicolas Poirier, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Dendritic cell; Myeloid cells; Tumor microenvironment |
| 213 | Poster Presentation | Use of A novel peptide ligand targeting multiple immune checkpoints: A novel approach to immunotherapy against Central Nervous System Tumors | Christopher Moertel; Zhengming Xiong; Michael Olin, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune suppression; Solid tumors |
| 214 | Poster Presentation | The effect of Anti-PD-1 therapy on median Overall Survival and Progression Free Survival in Glioblastoma Multiforme Patients with certain tumor markers | Awais Paracha, BA; Jian L. Campian, MD, PhD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Targeted therapy |
| 215 | Poster Presentation | AO-176, a highly differentiated clinical stage anti-CD47 antibody, preferentially binds tumor versus normal cell CD47 when complexed to β1 integrin | Robyn J. Puro, Ph.D; Prabir Chakraborty, Ph.D; John O. Richards, Ph.D; Ronald R. Hiebsch; Michael J. Donio, MS; W. Casey Wilson, Ph.D; Benjamin J. Capoccia, Ph.D; Carrie B. Brachmann, Ph.D; Vicki Sung, Ph.D; Arun K. Kashyap, Ph.D; Daniel S. Pereira, Ph.D; | Checkpoint Blockade Therapy | Antibody; Monocyte/Macrophage; Solid tumors; Targeted therapy; Tumor microenvironment |
| 216 | Poster Presentation | Anti-tumor activity of iosH2 by blocking LILRB2 receptor signalling | Osiris Marroquin Belaunzaran; Anahita Rafiei; Anil Kumar; Julia Kolibaba; Lorenz Vogt; Sean Smith; Christoph Renner; | Checkpoint Blockade Therapy | Checkpoint blockade; MDSC; Solid tumors; T cell |
| 217 | Poster Presentation | Evaluating biomarkers of JTX-8064 (anti-LILRB2/ILT4 monoclonal antibody) in an ex vivo human tumor histoculture system to inform clinical development | Yasmin L. Hashambhoy-Ramsay, PhD; Vikki Spaulding; Michelle Priess; Kristin O'Malley; Monica Gostissa, PhD; Edward C. Stack, PhD; Jeff Smith; Margaret Willer; Ben Umiker; Donald Shaffer, PhD; | Checkpoint Blockade Therapy | Antigen presenting cells; Biomarkers; Monocyte/Macrophage; Myeloid cells; RNA; Tumor evasion; Tumor microenvironment; Tumor stroma |
| 218 | Poster Presentation | A preclinical study of IMC-002, a fully human therapeutic antibody safely targeting CD47 in cancer | Hyeonseok Yoo, Ph.D.; Jeong Kook Kim, Ph.D.; Ji Yea Choi; Sun Kwang Song; Jihyun Park, Ph.D; Ara Jeon; Ji Hye Lee, MD; Sook Kyung Chang, Ph.D; Yun J. Song; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Monocyte/Macrophage; Myeloid cells; Solid tumors |
| 219 | Poster Presentation | Long-term clinical outcomes associated with sequential treatment of BRAF mutant advanced melanoma patients | Ahmad A. Tarhini, MD, PhD, MS; David F. McDermott, MD; Apoorva Ambavane, MPH; Agnes Benedict, MSc, MA; Cho-Han Lee; Corey Ritchings, PharmD; Brian Stwalley, PharmD; Meredith M. Regan, PhD; Michael B. Atkins, MD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Targeted therapy |
| 220 | Poster Presentation | Real-world outcomes of patients with resected stage IIIA melanoma treated with adjuvant nivolumab | Wolfram Samlowski, MD; Robert Nicholas, MD; Tayla Poretta, PharmD, MPH; Andriy Moshyk, MSc, MD; Jonathan Rajkumar, MPH; Anthony Salvatore, PharmD; Brian Stwalley, PharmD; Esmond D. Nwokeji, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Epidemiology; Immune adjuvant; Solid tumors |
| 221 | Poster Presentation | Poor performance status negatively affects survival benefit of immunotherapy in non-small cell lung cancer | Hameem I. Kawsar, MD, PhD; Pramod I. Gaudel, MD; Nahid Suleiman, MD, PharmaD; Mohammed Al-Jumayli, MD; Chao Huang, MD; Prakash Neupane, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune toxicity; Solid tumors |
| 222 | Poster Presentation | Increased PD-L1 Tumor Expression Correlates with High Rate of Response to PD-1 Inhibitors in Patients with Unresectable, Recurrent, and Metastatic Cutaneous Squamous Cell Carcinoma | Nate Bowers, MD, PhD; Kimberly Burcher, MD; Jess Savas, MD; Phillip Williford, MD; Laura Doerfler, MD; Hafiz Shabbir Patwa, PharmD, MD; Joshua Waltonen, MD; Christopher Sullivan, MD; James Brown, MD; Mercedes Porosnicu, MD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Gene expression |
| 223 | Poster Presentation | Racial differences in outcomes for metastatic Renal Cell Carcinoma (mRCC) patients managed on Immune-Checkpoint Inhibitor (ICI) therapy. | T. Anders Olsen, BA; Dylan J. Martini, BA; Subir Goyal, Ph.D; Yuan Liu, Ph.D; Sean T. Evans, BS; Benjamin L. Magod, BS; Jacqueline T. Brown, MD; Lauren Yantorni, NP; Greta A. Russler, MSN, FNP-BC; Sarah Caulfield, PharmD, BCOP; Jamie M. Goldman, MD; Bassel Nazha, MD; Wayne B. Harris, MD; Viraj A. Master, MD Ph.D; Omer Kucuk, MD; Bradley C. Carthon, MD Ph.D; Mehmet A. Bilen, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Clinical study; Immune toxicity; Solid tumors |
| 224 | Poster Presentation | Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis | Tamara A. Sussman, MD; Wei Wei, MS; Pauline Funchain, MD; Brian R. Gastman, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Solid tumors; T cell |
| 226 | Poster Presentation | Checkpoint blockade hastens a switch from an NKT dominant, TNF-alpha-driven to a CD4+/CD8+ IFN-gamma-driven immune response within MC-38 tumor-infiltrating lymphocytes | Shota Aoyama, MD; Ryosuke Nakagawa, MD; Satoshi Nemoto, MD; Patricio Perez Villarroel; James J. Mulé; Adam W. Mailloux, PhD; | Checkpoint Blockade Therapy | Tumor infiltrating lymphocytes (TILs) |
| 227 | Poster Presentation | Using 3D spheroid cultures towards personalized ex vivo profiling of immune checkpoint inhibitor efficacy in melanoma and non-small cell lung cancer | Kathryn Appleton, PhD; Katy A. Lassahn, MS; Ashley K. Elrod; Tessa DesRochers, PhD; | Checkpoint Blockade Therapy | Antibody; Biomarkers; Checkpoint blockade; Chemokine; Chemotherapy; T cell; T cell lineages; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 228 | Poster Presentation | Radiological dynamics and resistance types in patients with advanced melanoma treated with anti-PD-1 monotherapy | Xue Bai, MD; Michelle Kim; Gyulnara Kasumova; Lu Si; Bixia Tang; Chuanliang Cui; Xiaoling Yang; Xiaoting Wei; Justine V. Cohen, DO; Donald P. Lawrence, MD; Christine Freedman, RN; Riley Fadden, NP; Krista M. Rubin, NP, MS; Tatyana Sharova; Dennie Frederick; Keith Flaherty, MD; Ryan J. Sullivan, MD; Jun Guo; Genevieve M. Boland, MD, PhD; | Checkpoint Blockade Therapy | Clinical study |
| 229 | Poster Presentation | Discovery of ganglioside GM2 activator as a novel proteomic biomarker associated with response to treatment in first-line melanoma subjects treated with PD-1 immunotherapy | Kristina Beeler, Dr.; Jakob Vowinckel, PhD; Martin Soste; Domenico Mallardo, MD; Mariaelena Capone, MD; Madonna Gabriele, MD; Antonio Sorrentino, MD; Vito Vanella, MD; Kamil Sklodowski, PhD; Daniel Heinzmann, MSc; Paolo A. Ascierto, MD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Immune monitoring; Immune suppression; Metabolism; Proteomics; Tumor microenvironment |
| 230 | Poster Presentation | Single cell PIK3 gene expression patterns support duvelisib (PI3K-delta, gamma inhibitor) treatment of melanoma and other tumors after checkpoint inhibitor therapy | Samantha Hidy; David Weaver, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Gene expression; Targeted therapy |
| 231 | Poster Presentation | A novel discovery pipeline identifies melanoma-specific antibodies in patients responding to immune checkpoint inhibitors | Daniel Delitto, MD, PhD; Evan J. Lipson, MD; Daniel Delitto, MD, PhD; Laura Cappelli, MD; Klaus J. Busam, MD; Antony Rosen, MBChB, MS; Suzanne L. Topalian, MD; Livia Casciola-Rosen, PhD; | Checkpoint Blockade Therapy | Antibody; B cell; Biomarkers; Checkpoint blockade; Immune monitoring; Immune toxicity; Solid tumors; Tumor antigens |
| 232 | Poster Presentation | The Epithelial-to-Mesenchymal Transition (EMT) contributes to Immunosuppression in Breast Carcinomas and regulates their response to Immune Checkpoint Blockade | Anushka Dongre, PhD; Robert A. Weinberg, PhD; Mohammad Rashidian, PhD; Elinor Ng. Eaton; Ferenc Reinhardt; Prat Thiru; Maria Zagorulya; Sunita Nepal; Tuba Banaz; Anna Martner; Stefani Spranger, PhD; | Checkpoint Blockade Therapy | Biomarkers; Carcinogenesis; Checkpoint blockade; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| 233 | Poster Presentation | Gene expression analysis of immune checkpoint therapy in mouse tumor models reveals similarities and differences in immune cell populations and functional processes that reflect response to treatment | Dominic Pearce; Daniel Halligan; Patrick Fadden, PhD; Chassidy Hall; Amber Blackwell; Edgar R. Wood, Ph.D.; | Checkpoint Blockade Therapy | B cell; Gene expression; Monocyte/Macrophage; NK/NK T cell; Solid tumors; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 235 | Poster Presentation | Antigen presentation pathways prime melanoma patients for more durable response to anti–PD-1 checkpoint blockade therapy | Saurabh Garg, PhD; Eric A. Welsh; Bin Fang, PhD; Yuliana I. Hernandez; Trevor Rose; Jhanelle Gray; John M. Koomen, PhD; Anders E. Berglund, PhD; James J. Mule, PhD; Joseph Markowitz, MD, PhD; | Checkpoint Blockade Therapy | Antigen presenting cells; Biomarkers; Checkpoint blockade; Gene expression; Proteomics; RNA; Tumor microenvironment |
| 236 | Poster Presentation | Evaluation of PD-L1 Expression in Primary Lung Tumor and Metastatic Lymph Nodes in the Presence of Immune Cells | Chris Hansis; Xiaomei Wang, MD, PhD; Tao Wang; Gerald Feldman; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune contexture; Solid tumors; Targeted therapy |
| 237 | Poster Presentation | In vitro potency assays for immune checkpoint blockade using human primary cells, murine huGEMM immune cells and patient-derived tumor organoids | Xuefei Yan, PhD; Hongjuan Zhang, PhD; Jun Zhou; Jia Zheng; Shuang Zhu; Rui Zhang; Mingfa Zang; Annie Xiaoyu An; Xiaoxi Xu; Shuzong Wang; Kevin Qijin Xu; Davy Xuesong Ouang; Henry Q. Li; Yujun Huang; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Costimulation; T cell |
| 238 | Poster Presentation | Molecular dissection of tumor-immune microenvironment factors associated with response to checkpoint inhibitor therapy in non-small cell lung cancer patients using Nanostring Digital Spatial Profiling | Omar J. Jabado, PhD; Suzana Couto, PhD, DVM pathologist; Jordan Blum, PhD; Patrick Franken; Patricia Coutinho de Souza, PhD; Maria N. Jure-Kunkel, PhD, DVM; Nora Pencheva, PhD; Brandon W. Higgs, PhD; Kate Sasser, PhD; Mark Fereshteh, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Chemotherapy; Gene expression; Immune contexture; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 239 | Poster Presentation | Decr2 loss promotes resistance of tumor cells to immunotherapy by affecting CD8+ T cell-regulated tumor ferroptosis | Thomas F. Gajewski, MD, PhD; Emily Higgs, BA; Shuyin Li, PhD; Shuyin Li, PhD; Blake Flood, BS; Ken Hatogai; | Checkpoint Blockade Therapy | Checkpoint blockade; Metabolism |
| 240 | Poster Presentation | Identification of lung cancer mutational signatures and tumor drivers associated with specific bimodal PD-L1/TMB status. | Fernando J. Lopez-Diaz, PhD.; Lauryn Keeler; Sally Agersborg, MD.; Lawrence Weiss, MD.; Vincent Funari, PhD (CGMBS); | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Immune monitoring; Neoantigens; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 241 | Poster Presentation | Clinical Outcomes of Metastatic Melanoma Patients with Liver Metastases Treated with Anti-PD-1 Monotherapy Versus Combination Ipilimumab/Nivolumab | Vincent T. Ma, MD; Kent A. Griffith, MPH, MS; Jessica J. Waninger, BS; Stephanie Daignault-Newton, MS; Leslie A. Fecher, MD; Ajjai S. Alva, MBBS; Christopher D. Lao, MD, MPH; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Clinical study; Immune tolerance; Solid tumors |
| 242 | Poster Presentation | Monitoring MDSC – A Hurdle to Immune Checkpoints Inhibitors | Damien Montamat-Sicotte, PhD; Laetitia Cortes; Virginia Litwin; Henry Hepburne-Scott, PhD; Phoebe Bonner; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune suppression; MDSC |
| 243 | Poster Presentation | Real world exposure survival relationship of pembrolizumab in metastatic melanoma | Vishal Navani, MA (Oxon) MBBS (Lon) MRCP (UK); Moira C. Graves, PhD; Giovana Marchett, MD, FRACP; Hiren Mandaliya, MD, FRACP; Nikola Bowden, BSc, PhD; Andre Van der Westhuizen, MBChB, MMed (Internal Medicine), FRACP, MSc (Med); | Checkpoint Blockade Therapy | Antibody; Biomarkers; Checkpoint blockade; Solid tumors |
| 244 | Poster Presentation | Novel Respirable Antisense Oligonucleotide (RASON) approach to primary and metastatic human lung cancer: Preliminary results in a model system employing spontaneous lung tumors in dogs | Jonathan W. Nyce, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Epigenetics; NK/NK T cell; Solid tumors; Tumor evasion |
| 245 | Poster Presentation | Human TLR8 knock-in mice potentiate immunotherapy responses of MC38 syngeneic tumors | Shanshan Qi, PhD; Hongjuan Zhang, PhD; Ruilin Sun; Annie X. An; Henry Q. Li; Davy X. Ouyang, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Dendritic cell; T cell; TLR |
| 246 | Poster Presentation | Clinicopathologic and genomic correlates of tumor mutational burden and its impact on PD-(L)1 inhibition efficacy in non-small cell lung cancer according to different PD-L1 expression subgroups | Biagio Ricciuti, MD; Navin R. Mahadevan; Renato Umeton; Joao V. Alessi; Andrew Polio; Natalie Vokes; Giulia C. Leonardi; Elizabeth J. Aguilar; Gonzalo Recondo, MD; Giuseppe Lamberti, MD; Marissa Lawrence; Pasi A. Janne, MD PhD; Eliezer Van Allen, MD; Lynette M. Sholl, MD; Mark Awad, MD, PhD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade |
| 247 | Poster Presentation | Assessment of sensitivity to a PD-1 check point inhibitor and cisplatin in bladder cancer patient-derived xenografts with various levels of PD-L1 expression in HuCD34NCG mice | Simon Tarpinian, BS; Jenny Rowe, PhD; Ruziboy Husanov, MS; Uma Saha, MS; Prabal Banerjee, PhD; Rukiye Eraslan, PhD; Beverly Jones, PhD; Stephen Festin, PhD; Vladimir Khazak, PhD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Chemotherapy; Solid tumors; Stem cell/cancer-initiating cell |
| 248 | Oral Presentation | Immunotherapy persister cells uncovered by dynamic single-cell RNA-sequencing | Kartik Sehgal, MD; Andrew Portell; Elena Ivanova; Patrick Lizotte, PhD; Navin R. Mahadevan; Jonathan R. Greene; Amir Vadji; Carino Gurjao; Tyler Teceno; Luke J. Taus; Tran C. Thai; Shunsuke Kitajima; Derek Liu; Tetsuo Tani; Moataz Noureddine; Christie J. Lau; Paul T. Kirschmeier, PhD; David Liu, MD, MPH, MS; Marios Giannakis, MD, PhD; Russell W. Jenkins; Prafulla C. Gokhale, PhD; Silvia Goldoni; Maria Pinzon-Ortiz, BS; William D. Hastings; Peter Hammerman; Juan Miret; Cloud P. Paweletz, Ph.D.; David A. Barbie, MD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Gene expression; Stem cell/cancer-initiating cell; Targeted therapy; Tumor evasion |
| 249 | Poster Presentation | Targeting IFNβ-regulated secretory profiles to overcome acquired anti-PD-L1 resistance | Yuhao Shi, B.S.; Melissa Dolan; Michalis Mastri, PhD; Kevin H. Eng, PhD; John ML. Ebos, PhD; | Checkpoint Blockade Therapy | Bioinformatics; Biomarkers; Checkpoint blockade; Cytokine; Gene expression; Immune suppression; Inflammation; Tumor microenvironment; Tumor stroma |
| 250 | Poster Presentation | SEA-TGT is a nonfucosylated antibody with distinct and amplified effector function activity that leverages the dependencies of anti-TIGIT anti-tumor activity upon Fc?R engagement | Alyson J. Smith, PhD; Weiping Zeng; William Siegall; Bryan Grogan; Jane Haass; Amber Blackmarr; Robert Thurman; Scott Peterson; Shyra J. Gardai, PhD; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; NK/NK T cell; Regulatory T cell (Treg cell); T cell; Targeted therapy |
| 251 | Poster Presentation | Factors evaluated as predictors of exceptional response to PD-1 inhibitors in patients with head and neck squamous cell cancer | Alexander H. Song, MD; Ron Ng, MD; John Heller, MD; Robin Petro; Ralph B. D’Agostino, PhD; Thomas W. Lycan, Jr., DO; Mercedes Porosnicu, MD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade |
| 252 | Poster Presentation | Immune-related adverse events associated with immune checkpoint inhibitor therapy are associated with enhanced survival and disease-specific incidence | Eric J. Vick, MD, PhD; Inas Abuali, MD; Andrew Kelleher, MD; Sarah Ludvigsen, DO; Nathanael D. Moore, MD; Nicholas Arias; Shuchi Gulati, MD, FACP; Trisha M. Wise-Draper, MD, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune toxicity; Solid tumors |
| 253 | Poster Presentation | Anti-TIGIT antibodies require enhanced FcγR co-engagement for optimal T and NK cell-dependent anti-tumor immunity | Rebecca Ward, MSc; Elena Paltrinieri, PhD; Marilyn Marques; Priyadarshini Iyer, MSc; Sylvia Dietrich, PhD; Jeremy D. Waight, PhD; Mark Bushell, PhD; Nicholas Wilson, PhD; Jennifer S. Buell, PhD; David Savitsky, PhD; Dhan Chand, PhD; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; NK/NK T cell; T cell |
| 254 | Oral Presentation | CTLA-4 blockade promotes Treg glucose metabolism and reduces Treg functional stability in glycolysis-defective tumors. | Roberta Zappasodi, PhD; Inna Serganova; Ivan Cohen; Masatomo Maeda; Yasin Senbabaoglu; Masahiro Shindo; Rachana Maniyar, PhD; Mayuresh Mane; Avigdor Leftin; McLane Watson, BS; Svena Verma, BS; Matthew Lubin; Myat Kyaw Ko; Arnab Ghosh, MD, PhD; Mohsen Abu-Akeel, BS; Ellen Ackerstaff; Jason Koutcher; Ping-Chih Ho, PhD; Greg M. Delgoffe, PhD; Ronald Blasberg; Jedd D. Wolchok, MD, PhD; Taha Merghoub, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune suppression; Immune tolerance; Metabolism; Regulatory T cell (Treg cell); T cell; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 255 | Poster Presentation | Efficacy of sequential immune checkpoint inhibition (ICI) in patients with genitourinary malignancies | Sean T. Evans, BS; Dylan J. Martini, BA; Benjamin L. Magod, BS; Timothy A. Olsen, BA; Jacqueline T. Brown, MD; Lauren Yantorni, NP; Deepak Ravindranathan, MD, MS; Greta A. Russler, MSN, FNP-BC; Sarah Caulfield, PharmD, BCOP; Jamie M. Goldman, MD; Bassel Nazha, MD; Wayne B. Harris, MD; Viraj A. Master, MD Ph.D; Omer Kucuk, MD; Bradley C. Carthon, MD Ph.D; Mehmet A. Bilen, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Targeted therapy |
| 256 | Poster Presentation | Single-agent Zalifrelimab (anti-CTLA-4) Shows Clinical Benefit in Rare Tumors - Case Report from Phase 2 Study (NCT03104699). | Cesar A. Perez, MD; Robert Wesolowski, MD; Breelyn A. Wilky, MD; Waldo Ortuzar Feliu, MD; Hong Zhang; irina shapiro, PhD; Anna Wijatyk, MD; Remigiusz Kaleta, MD; Jonathan C. Trent, MD; | Checkpoint Blockade Therapy | Solid tumors |
| 774 | Poster Presentation | Antibiotic Administration Prior to Immunotherapy Leads to Poor Overall Survival Across Multiple Malignancies | Eric J. Vick, MD, PhD; Inas Abuali, MD; Sarah Ludvigsen, DO; Andrew Kelleher, MD; Nathanael D. Moore, MD; Nicholas Arias; Shuchi Gulati, MD, FACP; Trisha M. Wise-Draper, MD, PhD; | Checkpoint Blockade Therapy | Surfaceome; Bioinformatics; Checkpoint blockade; Clinical study |
| 775 | Poster Presentation | Rare case reports on thymic carcinoma patients treated with pembrolizumab | Evelyn Paszkan; Erna Ganofszky; Zsolt Megyesfalvi; Aron Ghimessy; Balazs Dome; Laszlo Agocs; Erika Toth; Ferenc Renyi-Vamos; Gabor Rubovszky; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Chemotherapy; Immune tolerance; Solid tumors |
| 776 | Poster Presentation | A role for immune checkpoint blockade to enhance T cell-mediated responses in combination with chemotherapy in oesophageal adenocarcinoma | Maria D. Davern, PhD; Joanne Lysaght; Andrew D. Sheppard; Stephen G. Maher; Noel E. Donlon, MRCS; John V. Reynolds, FRCS; Fiona O. Connell; Conall Hayes; Ross King; Anshul Bhardwaj; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Chemotherapy; Coinhibition; Costimulation; Immune tolerance; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 778 | Poster Presentation | Preclinical Study Using a Glutamatergic Signaling and Immune-Checkpoint Inhibitors in a Spontaneous Melanoma Prone Mouse Model | Kevinn Eddy, B.A; Christina Marinaro, B.S; Maryam Rasheed, B.A; Joseph Campagnolo; Xiaoxuan Zhong; Mohamad Na. Eddin; Raj Shah, PhD; Kajal Gupta, Ph.D; Jesus Diaz, M.S; Andrew Zloza, MD, PhD; Suzie Chen, PhD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Chemokine; Cytokine; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| 779 | Poster Presentation | Immune checkpoint blockade impacts the suppressive phenotype and function of regulatory T cells in an endogenous mouse lymphoma model | Vera Bauer, Doctoral candidate; Fatima Ahmetlic; Martin Roecken; Ralph Mocikat; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune suppression; Leukemia/Lymphoma; Regulatory T cell (Treg cell); Tumor microenvironment |
| 780 | Poster Presentation | Quantitative Cell-Based Bioassays to Advance Immunotherapy Programs Targeting Immune Checkpoint Receptors | Jamison J. Grailer, PhD; Julia Gilden, Ph.D.; Pete Stecha, BS; Denise Garvin, BS; Jun Wang; Michael Beck, MS; Jim Hartnett, BS; Gopal B. Krishnan; Frank Fan, PhD; Mei Cong, PhD; Zhi-jie J. Cheng, PhD; | Checkpoint Blockade Therapy | Adoptive immunotherapy; Antibody; Antigen presenting cells; Checkpoint blockade; T cell; Targeted therapy; Vaccine |
| 781 | Poster Presentation | Validation of the Combinatorial Effect of Blinatumomab and Nivolumab in Cancer Therapy | Tienan Wang, PhD; Qing Lin; Jie Zhang; | Checkpoint Blockade Therapy | Bispecifics; Adoptive immunotherapy; Antibody; Checkpoint blockade; Clinical trial; T cell; Tumor antigens |
| 782 | Poster Presentation | ALDH1A inhibition as adjuvant to ovarian cancer immunotherapy | Bingsi Gao; Mainpal Rana, PhD; Dongli Yang, PhD; Edward Grimley; Stacy McGonigal; Ronald P. Buckanovich, MD.PhD; Anda M. Vlad, MD, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune adjuvant; Monocyte/Macrophage; Regulatory T cell (Treg cell); T cell |
| 785 | Poster Presentation | Estrogen-deprivation promotes Th1 polarization of tumor-associated T cells in a mouse model of high grade serous ovarian cancer | Daniel M. Falcon, PhD; Marina D. Miller, MD; Chelsea D. Goff; Ichiko Kinjyo, MD PhD; Sarah F. Adams, MD; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Chemotherapy; Coinhibition; Immune suppression; Regulatory T cell (Treg cell); T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 786 | Poster Presentation | Distinct efficacy and immunological responses to aPD-1, aPD-L1 and aPD-L2 immunotherapy in B16 melanoma in aged versus young hosts includes T-cell stem cell effects and PD-L2 expression differences | Myrna G. Garcia, BS; Alvaro S. Padron; Yilun Deng, MD, PhD; Aravind Kancharla, MS; Ryan M. Reyes, BS; Harshita B. Gupta, PhD; Tyler J. Curiel, MD, MPH; | Checkpoint Blockade Therapy | Checkpoint blockade; Cytokine; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
